INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,463 | -26.0% | 18,418 | -55.8% | 0.00% | 0.0% |
| Q2 2023 | $461,158 | -19.2% | 41,696 | -1.9% | 0.00% | 0.0% |
| Q1 2023 | $570,585 | +0.4% | 42,486 | -7.4% | 0.00% | 0.0% |
| Q4 2022 | $568,470 | +215.8% | 45,899 | +255.0% | 0.00% | – |
| Q3 2022 | $180,000 | -2.2% | 12,931 | -2.7% | 0.00% | – |
| Q2 2022 | $184,000 | -17.1% | 13,293 | -3.0% | 0.00% | – |
| Q1 2022 | $222,000 | -12.9% | 13,702 | -12.5% | 0.00% | – |
| Q4 2021 | $255,000 | +8.1% | 15,662 | -1.5% | 0.00% | – |
| Q3 2021 | $236,000 | -27.2% | 15,901 | -2.3% | 0.00% | -100.0% |
| Q2 2021 | $324,000 | -68.3% | 16,278 | -63.3% | 0.00% | -50.0% |
| Q1 2021 | $1,023,000 | -23.8% | 44,328 | -18.5% | 0.00% | -50.0% |
| Q4 2020 | $1,343,000 | -56.5% | 54,405 | -26.9% | 0.00% | -55.6% |
| Q3 2020 | $3,090,000 | -14.5% | 74,398 | -1.3% | 0.01% | -25.0% |
| Q2 2020 | $3,612,000 | -23.7% | 75,398 | +0.4% | 0.01% | -36.8% |
| Q1 2020 | $4,732,000 | – | 75,135 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |